You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy
|
|---|---|
| Published in |
Frontiers in oncology, April 2018
|
| DOI | 10.3389/fonc.2018.00107 |
| Pubmed ID | |
| Authors |
Preeti Kanikarla-Marie, Michael Lam, Alexey V. Sorokin, Michael J. Overman, Scott Kopetz, David G. Menter |
| Abstract |
The role of platelets in cancer progression has been well recognized in the field of cancer biology. Emerging studies are elaborating further the additional roles and added extent that platelets play in promoting tumorigenesis. Platelets release factors that support tumor growth and also form heterotypic aggregates with tumor cells, which can provide an immune-evasive advantage. Their most critical role may be the inhibition of immune cell function that can negatively impact the body's ability in preventing tumor establishment and growth. This review summarizes the importance of platelets in tumor progression, therapeutic response, survival, and finally the notion of immunotherapy modulation being likely to benefit from the inclusion of platelet inhibitors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 21% |
| Student > Ph. D. Student | 5 | 13% |
| Student > Bachelor | 4 | 11% |
| Student > Master | 4 | 11% |
| Professor > Associate Professor | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 11 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 6 | 16% |
| Medicine and Dentistry | 6 | 16% |
| Agricultural and Biological Sciences | 3 | 8% |
| Engineering | 2 | 5% |
| Nursing and Health Professions | 1 | 3% |
| Other | 6 | 16% |
| Unknown | 14 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2018.
All research outputs
#22,905,350
of 25,540,105 outputs
Outputs from Frontiers in oncology
#16,130
of 22,658 outputs
Outputs of similar age
#300,741
of 340,917 outputs
Outputs of similar age from Frontiers in oncology
#114
of 147 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,658 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,917 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.